<DOC>
	<DOCNO>NCT00377377</DOCNO>
	<brief_summary>EP01572 peptidomimetic growth hormone secretagogue , potent GH-releasing activity intravenous administration.It analogue natural compound ghrelin . Since oral delivery system would preferable many possible therapeutic indication , pharmacological profile GH-releasing activity increase single , oral dos EP01572 healthy volunteer evaluate . In addition , pharmacokinetics pharmacological effect EP01572 investigate intraduodenal administration .</brief_summary>
	<brief_title>Oral Ghrelin Agonist Healthy Subjects</brief_title>
	<detailed_description>EP01572 willbe give orally 36 male subject ; treatment consist one oral dose either EP01572 placebo ( 0.005 , 0.05 0.5 mg/kg body weight ) . Subjects receive one dose EP01572 placebo . Six subject receive two additional oral dos EP01572 : 0.125 0.25 mg/kg body weight . In another part , 6 subject receive follow treatment randomize order : 1 ) administration bolus saline ( placebo ) small intestine ; 2 ) intraduodenal ( ID ) administration bolus EP01572 0.2 mg/kg body weight ; 3 ) ID perfusion bolus EP01572 0.35 mg/kg body weight ; 4 ) ID perfusion bolus EP01572 0.5 mg/kg body weight .</detailed_description>
	<criteria>Healthy male Females</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>July 2006</verification_date>
	<keyword>GH release</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Safety</keyword>
</DOC>